Long-term persistence of symptomatic effect of selegiline in parkinson’s disease, a two-months placebo-controlled withdrawal study View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2001-06

AUTHORS

A. Negrotti, G. Bizzarri, S. Calzetti

ABSTRACT

Following a two-months of placebo-controlled withdrawal, the MAO-B inhibitor selegiline was found to maintain a long term significant mild to moderate symptomatic effect on bradykinesia and tremor at rest in nine patients with Parkinson's disease (stage II and III of H&Y), whose functional impairment had also required a dopaminergic therapy with low-dose bromocriptine. Both motor signs found worsened during the wash-out showed a full recovery to pre-withdrawal condition within two months after reinstitution of the drug. More... »

PAGES

215-219

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s007020170089

DOI

http://dx.doi.org/10.1007/s007020170089

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1032412892

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/11314774


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antiparkinson Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bromocriptine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Motor Activity", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Parkinson Disease", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Selegiline", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Severity of Illness Index", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Single-Blind Method", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Substance Withdrawal Syndrome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of Parma", 
          "id": "https://www.grid.ac/institutes/grid.10383.39", 
          "name": [
            "Istituto di Neurologia, Universit\u00e0 di Parma, Parma, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Negrotti", 
        "givenName": "A.", 
        "id": "sg:person.0727043621.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0727043621.37"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Parma", 
          "id": "https://www.grid.ac/institutes/grid.10383.39", 
          "name": [
            "Istituto di Neurologia, Universit\u00e0 di Parma, Parma, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bizzarri", 
        "givenName": "G.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Parma", 
          "id": "https://www.grid.ac/institutes/grid.10383.39", 
          "name": [
            "Istituto di Neurologia, Universit\u00e0 di Parma, Parma, Italy", 
            "Istituto di Neurologia, Strada del Quartiere, 4, I-43100, Parma, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Calzetti", 
        "givenName": "S.", 
        "id": "sg:person.01017132256.80", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01017132256.80"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1097/00002826-199506000-00005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005330764"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/ana.410380512", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030000219"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm199301213280305", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045752174"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/wnl.47.6_suppl_3.196s", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064374569"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/wnl.47.6_suppl_3.196s", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064374569"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/wnl.47.6_suppl_3.196s", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064374569"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/wnl.47.6_suppl_3.200s", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064374570"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/wnl.47.6_suppl_3.200s", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064374570"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/wnl.47.6_suppl_3.200s", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064374570"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/wnl.51.2.520", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064376556"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/wnl.51.2.520", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064376556"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/wnl.51.2.520", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064376556"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2001-06", 
    "datePublishedReg": "2001-06-01", 
    "description": "Following a two-months of placebo-controlled withdrawal, the MAO-B inhibitor selegiline was found to maintain a long term significant mild to moderate symptomatic effect on bradykinesia and tremor at rest in nine patients with Parkinson's disease (stage II and III of H&Y), whose functional impairment had also required a dopaminergic therapy with low-dose bromocriptine. Both motor signs found worsened during the wash-out showed a full recovery to pre-withdrawal condition within two months after reinstitution of the drug.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s007020170089", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1312227", 
        "issn": [
          "0300-9564", 
          "1435-1463"
        ], 
        "name": "Journal of Neural Transmission", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "108"
      }
    ], 
    "name": "Long-term persistence of symptomatic effect of selegiline in parkinson\u2019s disease, a two-months placebo-controlled withdrawal study", 
    "pagination": "215-219", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "9a68e160ecb837580db389c0e0b97e0558293a38a066d1536adcbb76feabba59"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "11314774"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "9702341"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s007020170089"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1032412892"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s007020170089", 
      "https://app.dimensions.ai/details/publication/pub.1032412892"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T14:32", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000373_0000000373/records_13102_00000001.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007/s007020170089"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s007020170089'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s007020170089'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s007020170089'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s007020170089'


 

This table displays all metadata directly associated to this object as RDF triples.

153 TRIPLES      21 PREDICATES      48 URIs      34 LITERALS      22 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s007020170089 schema:about N0533b957a7de42448d3a77921744292a
2 N1ba85552ced14c7294f287cea4179eb1
3 N1bf973da6d8343c88bb0eb66d7f78448
4 N5c3349eda39a4974852f7f1ef291d036
5 N6fa46e3d463f4662850c0f20c4e19817
6 N7c804e3093694f7bbcc82d881a045822
7 N9a2c87b21fce400eb2812e71f33387c8
8 Na7878f3b7e2745d7809287e1beacbe83
9 Nb6c35921102e4b3395faf8548248f1eb
10 Nc618945033f049989c96f42e6dc893be
11 Nc758b0adf5a64d36ba50c5030ad04631
12 Ndc597db939f2403dac257dac7eb656fd
13 Ne7f6869885104de59b581271d137323c
14 anzsrc-for:11
15 anzsrc-for:1102
16 schema:author Nfac070974be54a3cb48fea4e397a1a46
17 schema:citation https://doi.org/10.1002/ana.410380512
18 https://doi.org/10.1056/nejm199301213280305
19 https://doi.org/10.1097/00002826-199506000-00005
20 https://doi.org/10.1212/wnl.47.6_suppl_3.196s
21 https://doi.org/10.1212/wnl.47.6_suppl_3.200s
22 https://doi.org/10.1212/wnl.51.2.520
23 schema:datePublished 2001-06
24 schema:datePublishedReg 2001-06-01
25 schema:description Following a two-months of placebo-controlled withdrawal, the MAO-B inhibitor selegiline was found to maintain a long term significant mild to moderate symptomatic effect on bradykinesia and tremor at rest in nine patients with Parkinson's disease (stage II and III of H&Y), whose functional impairment had also required a dopaminergic therapy with low-dose bromocriptine. Both motor signs found worsened during the wash-out showed a full recovery to pre-withdrawal condition within two months after reinstitution of the drug.
26 schema:genre research_article
27 schema:inLanguage en
28 schema:isAccessibleForFree false
29 schema:isPartOf N4e84745c018549468a04813586ac34d1
30 N6df9e58c42474d018c76c8b7bc14f6ba
31 sg:journal.1312227
32 schema:name Long-term persistence of symptomatic effect of selegiline in parkinson’s disease, a two-months placebo-controlled withdrawal study
33 schema:pagination 215-219
34 schema:productId N0a816c0458294e01b3b6bf0f3dd67daf
35 N365e665a62244736af208cef5f8868da
36 N655ff42eb6374669afc1bf1776a59b6b
37 Nc7c4a3eff9fe477894bc4f30d5393e20
38 Nd1676e2d3d7f4619a4eb148d9ed96922
39 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032412892
40 https://doi.org/10.1007/s007020170089
41 schema:sdDatePublished 2019-04-11T14:32
42 schema:sdLicense https://scigraph.springernature.com/explorer/license/
43 schema:sdPublisher Nc0f91b151b6942f0828be0e62b0a399c
44 schema:url http://link.springer.com/10.1007/s007020170089
45 sgo:license sg:explorer/license/
46 sgo:sdDataset articles
47 rdf:type schema:ScholarlyArticle
48 N0533b957a7de42448d3a77921744292a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
49 schema:name Antiparkinson Agents
50 rdf:type schema:DefinedTerm
51 N0a816c0458294e01b3b6bf0f3dd67daf schema:name nlm_unique_id
52 schema:value 9702341
53 rdf:type schema:PropertyValue
54 N1ba85552ced14c7294f287cea4179eb1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
55 schema:name Substance Withdrawal Syndrome
56 rdf:type schema:DefinedTerm
57 N1bf973da6d8343c88bb0eb66d7f78448 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
58 schema:name Female
59 rdf:type schema:DefinedTerm
60 N221059977f694d819deb06888449d335 rdf:first sg:person.01017132256.80
61 rdf:rest rdf:nil
62 N365e665a62244736af208cef5f8868da schema:name doi
63 schema:value 10.1007/s007020170089
64 rdf:type schema:PropertyValue
65 N3a1093c134a24e1fba393c04ddbffcd0 schema:affiliation https://www.grid.ac/institutes/grid.10383.39
66 schema:familyName Bizzarri
67 schema:givenName G.
68 rdf:type schema:Person
69 N4e84745c018549468a04813586ac34d1 schema:issueNumber 2
70 rdf:type schema:PublicationIssue
71 N5c3349eda39a4974852f7f1ef291d036 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
72 schema:name Severity of Illness Index
73 rdf:type schema:DefinedTerm
74 N655ff42eb6374669afc1bf1776a59b6b schema:name dimensions_id
75 schema:value pub.1032412892
76 rdf:type schema:PropertyValue
77 N6df9e58c42474d018c76c8b7bc14f6ba schema:volumeNumber 108
78 rdf:type schema:PublicationVolume
79 N6fa46e3d463f4662850c0f20c4e19817 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
80 schema:name Middle Aged
81 rdf:type schema:DefinedTerm
82 N7c804e3093694f7bbcc82d881a045822 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
83 schema:name Single-Blind Method
84 rdf:type schema:DefinedTerm
85 N9a2c87b21fce400eb2812e71f33387c8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
86 schema:name Selegiline
87 rdf:type schema:DefinedTerm
88 Na7878f3b7e2745d7809287e1beacbe83 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
89 schema:name Bromocriptine
90 rdf:type schema:DefinedTerm
91 Nb6c35921102e4b3395faf8548248f1eb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
92 schema:name Male
93 rdf:type schema:DefinedTerm
94 Nc0f91b151b6942f0828be0e62b0a399c schema:name Springer Nature - SN SciGraph project
95 rdf:type schema:Organization
96 Nc3b13a2bac644c5cb07c4526f2f2fd42 rdf:first N3a1093c134a24e1fba393c04ddbffcd0
97 rdf:rest N221059977f694d819deb06888449d335
98 Nc618945033f049989c96f42e6dc893be schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Aged
100 rdf:type schema:DefinedTerm
101 Nc758b0adf5a64d36ba50c5030ad04631 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Humans
103 rdf:type schema:DefinedTerm
104 Nc7c4a3eff9fe477894bc4f30d5393e20 schema:name readcube_id
105 schema:value 9a68e160ecb837580db389c0e0b97e0558293a38a066d1536adcbb76feabba59
106 rdf:type schema:PropertyValue
107 Nd1676e2d3d7f4619a4eb148d9ed96922 schema:name pubmed_id
108 schema:value 11314774
109 rdf:type schema:PropertyValue
110 Ndc597db939f2403dac257dac7eb656fd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Motor Activity
112 rdf:type schema:DefinedTerm
113 Ne7f6869885104de59b581271d137323c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Parkinson Disease
115 rdf:type schema:DefinedTerm
116 Nfac070974be54a3cb48fea4e397a1a46 rdf:first sg:person.0727043621.37
117 rdf:rest Nc3b13a2bac644c5cb07c4526f2f2fd42
118 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
119 schema:name Medical and Health Sciences
120 rdf:type schema:DefinedTerm
121 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
122 schema:name Cardiorespiratory Medicine and Haematology
123 rdf:type schema:DefinedTerm
124 sg:journal.1312227 schema:issn 0300-9564
125 1435-1463
126 schema:name Journal of Neural Transmission
127 rdf:type schema:Periodical
128 sg:person.01017132256.80 schema:affiliation https://www.grid.ac/institutes/grid.10383.39
129 schema:familyName Calzetti
130 schema:givenName S.
131 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01017132256.80
132 rdf:type schema:Person
133 sg:person.0727043621.37 schema:affiliation https://www.grid.ac/institutes/grid.10383.39
134 schema:familyName Negrotti
135 schema:givenName A.
136 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0727043621.37
137 rdf:type schema:Person
138 https://doi.org/10.1002/ana.410380512 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030000219
139 rdf:type schema:CreativeWork
140 https://doi.org/10.1056/nejm199301213280305 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045752174
141 rdf:type schema:CreativeWork
142 https://doi.org/10.1097/00002826-199506000-00005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005330764
143 rdf:type schema:CreativeWork
144 https://doi.org/10.1212/wnl.47.6_suppl_3.196s schema:sameAs https://app.dimensions.ai/details/publication/pub.1064374569
145 rdf:type schema:CreativeWork
146 https://doi.org/10.1212/wnl.47.6_suppl_3.200s schema:sameAs https://app.dimensions.ai/details/publication/pub.1064374570
147 rdf:type schema:CreativeWork
148 https://doi.org/10.1212/wnl.51.2.520 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064376556
149 rdf:type schema:CreativeWork
150 https://www.grid.ac/institutes/grid.10383.39 schema:alternateName University of Parma
151 schema:name Istituto di Neurologia, Strada del Quartiere, 4, I-43100, Parma, Italy
152 Istituto di Neurologia, Università di Parma, Parma, Italy
153 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...